Hologic

Hologic (Template:Nasdaq) corporation is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications. It's core business units are focused on osteoporosis assessment, mammography and breast biopsy, direct-to-digital x-ray for general radiography applications and mini C-arm imaging for orthopedic applications. Its major brands include Lorad, Fluoroscan, Selenia, Securview, Discovery, Multicare and Directray.

Hologic is a leader in women's healthcare, particularly breast cancer diagnosis. ^[1]

Hologic is currencly developing tomosynthesis technology for breast cancer diagnosis. Hologic first demonstrated the technology at the Radiological Society of North America in November 2003. It provided patient images and a prototype add-on to its Selenia digital mammography system. Clinical trials for Hologic's tomosynthesis technology began in the summer of 2004. ^[2]

Hologic was the recipient of Frost and Sullivan's 2004 Technology Leadership of the Year Award in women's healthcare. ^[3]

Hologic/Cytyc Merger

On May 20, 2007, Hologic announced a merger (via a cash and stock transaction) with the Cytyc Corporation to create a $10 billion women's healthcare company with over $1 billion in projected annual sales.^[4] The new company name will be "Hologic" and Cytyc will be a wholly-owned subsidiary. The combined corporation will deal in products for screening, diagnostics and therapy for breast and cervical cancer, menorrhagia, prenatal health, osteoporosis, endometriosis and permanent contraception.^[5] The brands under the combined company include, ThinPrep(R), Lorad(R), NovaSure(R), Suros ATEC(R), Discovery(TM), FullTerm(R), R2(R) and MammoSite(R), and it will have operations in over twenty countries.^[6] Patrick Sullivan, of Cytyc will be chairman of the new company, and Jack Cumming, of Hologic, will be Chief Executive Officer.^[7] Cytyc shareholders will hold 55% of the firm, and Hologic will own 45%.